Clinical manifestations and evaluation of postmenopausal vulvovaginal atrophy

References

• Rees M, Pérez-López FR, Ceasu I, et al. EMAS clinical guide: low-dose vaginal estrogens for postmenopausal vaginal atrophy. Maturitas. 2012;73(2):171–174.
   PubMed Web of Science ®Google Scholar
• Gold EB. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40–55 years of age. Am J Epidemiol. 2000;152(5):463–473.
   PubMed Web of Science ®Google Scholar
• DiBonaventura M, Luo X, Moffatt M, et al. The association between vulvovaginal atrophy symptoms and quality of life among postmenopausal women in the United States and Western Europe. J Women’s Health. 2015;24(9):713–722.
   PubMed Web of Science ®Google Scholar
• Portman DJ, Gass MLS, Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Maturitas. 2014;79(3):349–354.
   PubMed Web of Science ®Google Scholar
• Vieira-Baptista P, Grincevičienė Š, Oliveira C, et al. The International Society for the Study of vulvovaginal disease vaginal wet mount microscopy guidelines: how to perform, applications, and interpretation. J Low Genit Tract Dis. 2021;25(2):172–180.
   PubMed Web of Science ®Google Scholar
• Palma F, Volpe A, Villa P, et al. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: the AGATA study. Maturitas. 2016;83:40–44.
   PubMed Web of Science ®Google Scholar
• Biglia N, Bounous VE, D'Alonzo M, et al. Vaginal atrophy in breast cancer survivors: attitude and approaches among oncologists. Clin Breast Cancer. 2017;17(8):611–617.
   PubMed Web of Science ®Google Scholar
• Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87–94.
   PubMed Web of Science ®Google Scholar
• Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA. 2011;108(Suppl. 1):4680–4687.
   PubMed Web of Science ®Google Scholar
• Brotman RM, Shardell MD, Gajer P, et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause. 2014;21(5):450–458.
   PubMed Web of Science ®Google Scholar
• Huang B, Fettweis JM, Brooks JP, et al. The changing landscape of the vaginal microbiome. Clin Lab Med. 2014;34(4):747–761.
   PubMed Web of Science ®Google Scholar
• Diop K, Dufour JC, Levasseur A, et al. Exhaustive repertoire of human vaginal microbiota. Hum Microbiome J. 2019;11:100051.
   Google Scholar
• Leckie KJ. What is the evidence for the role of oestrogen in the prevention of recurrent urinary tract infections in postmenopausal women? An evidence-based review. J Clin Gerontol Geriatr. 2010;1(2):31–35.
   Google Scholar
• Mitchell CM, Waetjen LE. Genitourinary changes with aging. Obstet Gynecol Clin N Am. 2018;45(4):737–750.
   PubMed Web of Science ®Google Scholar
• Brotman RM, Shardell MD, Gajer P, et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause. 2018;25(11):1321–1330.
   PubMed Web of Science ®Google Scholar
• Shen J, Song N, Williams CJ, et al. Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis. Sci Rep. 2016;6:24380 [Erratum in: Sci Rep. 2016;6:34119].
   PubMed Web of Science ®Google Scholar
• Farage M, Maibach H. Lifetime changes in the vulva and vagina. Arch Gynecol Obstet. 2006;273(4):195–202.
   PubMedGoogle Scholar
• Zerbinati N, Serati M, Origoni M, et al. Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. Lasers Med Sci. 2015;30(1):429–436.
   PubMed Web of Science ®Google Scholar
• Ferrante KL, Wasenda EJ, Jung CE, et al. Vaginal estrogen for the prevention of recurrent urinary tract infection in postmenopausal women: a randomized clinical trial. Female Pelvic Med Reconstr Surg. 2021;27(2):112–117.
   PubMed Web of Science ®Google Scholar
• Thomas-White K, Taege S, Limeira R, et al. Vaginal estrogen therapy is associated with increased Lactobacillus in the urine of postmenopausal women with overactive bladder symptoms. Am J Obstet Gynecol. 2020;223(5):727.e1–727.e11.
   Web of Science ®Google Scholar
• Weber MA, Limpens J, Roovers JPWR. Assessment of vaginal atrophy: a review. Int Urogynecol J. 2015;26(1):15–28.
   PubMed Web of Science ®Google Scholar
• Pérez-López FR, Vieira-Baptista P. Lichen sclerosus in women: a review. Climacteric. 2017;20(4):339–347.
   PubMed Web of Science ®Google Scholar
• Vieira-Baptista P, Lima-Silva J, Pérez-López FR, et al. A disease commonly hidden in plain sight. Case Rep Women’s Health. 2018;20:e00079.
   PubMedGoogle Scholar
• Lyra J, Vieira-Baptista P. Vulvar dermatoses and menopause. In: Postmenopausal diseases and disorders. Springer International Publishing; 2019. p. 101–120.
   Google Scholar
• Ringel NE, Iglesia C. Common benign chronic vulvar disorders. Am Fam Physician. 2020;102(9):550–557.
   PubMed Web of Science ®Google Scholar
• Graziottin A, Murina F, Gambini D, et al. Vulvar pain: the revealing scenario of leading comorbidities in 1183 cases. Eur J Obstet Gynecol Reprod Biol. 2020;252:50–55.
   PubMed Web of Science ®Google Scholar
• Saghatchian M, Lesur A. Gestion des effets secondaires de l’hormonothérapie du cancer du sein chez la femme jeune. Bull Cancer. 2019;106(12):S37–S42.
   PubMedGoogle Scholar
• Alperin M, Burnett L, Lukacz E, et al. The mysteries of menopause and urogynecologic health: clinical and scientific gaps. Menopause. 2019;26(1):103–111.
   PubMed Web of Science ®Google Scholar
• Llaneza P, Fernández‐Iñarrea JM, Arnott B, et al. Sexual function assessment in postmenopausal women with the 14‐item changes in Sexual Functioning Questionnaire. J Sex Med. 2011;8(8):2144–2151.
   PubMed Web of Science ®Google Scholar
• Erekson EA, Li F-Y, Martin DK, et al. Vulvovaginal symptoms prevalence in postmenopausal women and relationship to other menopausal symptoms and pelvic floor disorders. Menopause. 2016;23(4):368–375.
   PubMed Web of Science ®Google Scholar
• Fernández-Alonso AM, Cuerva MJ, Chedraui P, et al. Screening and management of female sexual dysfunction during the second half of life. In: Postmenopausal diseases and disorders. Springer International Publishing; 2019. p. 165–185.
   Google Scholar
• Santoro N, Worsley R, Miller KK, et al. Role of estrogens and estrogen-like compounds in female sexual function and dysfunction. J Sex Med. 2016;13(3):305–316.
   PubMed Web of Science ®Google Scholar
• Jones HJ, Huang AJ, Subak LL, et al. Bladder symptoms in the early menopausal transition. J Women’s Health. 2016;25(5):457–463.
   PubMed Web of Science ®Google Scholar
• Terauchi M, Hirose A, Akiyoshi M, et al. Prevalence and predictors of storage lower urinary tract symptoms in perimenopausal and postmenopausal women attending a menopause clinic. Menopause. 2015;22(10):1084–1090.
   PubMed Web of Science ®Google Scholar
• Hsu A, Nakagawa S, Walter LC, et al. The burden of nocturia among middle-aged and older women. Obstet Gynecol. 2015;125(1):35–43.
   PubMed Web of Science ®Google Scholar
• Daugherty M, Ginzburg N, Byler T. Prevalence of nocturia in United States women: results from national health and nutrition examination survey. Female Pelvic Med Reconstr Surg. 2021;27(1):e52–e58.
   PubMed Web of Science ®Google Scholar
• Bower WF, Whishaw DM, Khan F. Nocturia as a marker of poor health: causal associations to inform care. Neurourol Urodyn. 2017;36(3):697–705.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration; Most bothersome symptoms (MBS). Guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms—recommendations for clinical evaluation. Rockville (MD): US Food and Drug Administration; 2003.
   Google Scholar
• Huang AJ, Gregorich SE, Kuppermann M, et al. Day-to-Day Impact of Vaginal Aging Questionnaire: a multidimensional measure of the impact of vaginal symptoms on functioning and well-being in postmenopausal women. Menopause. 2015;22(2):144–154.
   PubMed Web of Science ®Google Scholar
• Eaton AA, Baser RE, Seidel B, et al. Validation of clinical tools for vaginal and vulvar symptom assessment in cancer patients and survivors. J Sex Med. 2017;14(1):144–151.
   PubMed Web of Science ®Google Scholar
• Avery K, Donovan J, Peters T, et al. The ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn. 2004;23(4):322–330.
   PubMed Web of Science ®Google Scholar
• Bornstein J, Goldstein AT, Stockdale CK, et al. 2015 ISSVD, ISSWSH, and IPPS consensus terminology and classification of persistent vulvar pain and vulvodynia. J Low Genit Tract Dis. 2016;20(2):126–130.
   PubMed Web of Science ®Google Scholar
• Vieira-Baptista P, Donders G, Margesson L, et al. Diagnosis and management of vulvodynia in postmenopausal women. Maturitas. 2018;108:84–94.
   PubMed Web of Science ®Google Scholar
• Dargie E, Holden RR, Pukall CF. The Vulvar Pain Assessment Questionnaire: factor structure, preliminary norms, internal consistency, and test–retest reliability. J Sex Med. 2017;14(12):1585–1596.
   PubMed Web of Science ®Google Scholar
• Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191–208.
   PubMed Web of Science ®Google Scholar
• Wiegel M, Meston C, Rosen R. The Female Sexual Function Index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31(1):1–20.
   PubMed Web of Science ®Google Scholar
• Isidori AM, Pozza C, Esposito K, et al. Development and validation of a 6-item version of the Female Sexual Function Index (FSFI) as a diagnostic tool for female sexual dysfunction. J Sex Med. 2010;7(3):1139–1146.
   PubMed Web of Science ®Google Scholar
• Pérez-López FR, Fernández-Alonso AM, Trabalón-Pastor M, et al. Assessment of sexual function and related factors in mid-aged sexually active Spanish women with the six-item Female Sex Function Index. Menopause. 2012;19(11):1224–1230.
   PubMed Web of Science ®Google Scholar
• Derogatis L, Clayton A, Lewis-D'Agostino D, et al. Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder. J Sex Med. 2008;5(2):357–364.
   PubMed Web of Science ®Google Scholar
• Clayton AH, Kingsberg SA, Goldstein I. Evaluation and management of hypoactive sexual desire disorder. Sex Med. 2018;6(2):59–74.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Guida M, Marchesoni D, et al. Vulvovaginal atrophy of menopause and its impact on sexual function in an Italian clinical cohort of post-menopausal women. J Obstet Gynaecol. 2021;41(2):290–297.
   PubMedGoogle Scholar
• Nappi RE, Graziottin A, Mollaioli D, et al. The Gynogram: a multicentric validation of a new psychometric tool to assess coital pain associated with VVA and its impact on sexual quality of life in menopausal women. J Sex Med. 2021;18(5):955–965.
   PubMed Web of Science ®Google Scholar
• Bachmann GA, Notelovitz M, Kelly SJ, et al. Long-term nonhormonal treatment of vaginal dryness. Clin Pract Sex. 1992;8:1–12.
   Google Scholar
• Vieira-Baptista P, Lima-Silva J, Beires J, et al. Women without vulvodynia can have a positive ‘Q-tip test’: a cross sectional study. J Psychosom Obstet Gynecol. 2017;38(4):256–259.
   PubMed Web of Science ®Google Scholar
• Caillouette JC, Sharp CF, Zimmerman GJ, et al. Vaginal pH as a marker for bacterial pathogens and menopausal status. Am J Obstet Gynecol. 1997;176(6):1270–1277.
   PubMed Web of Science ®Google Scholar
• Roy S, Caillouette JC, Roy T, et al. Vaginal pH is similar to follicle-stimulating hormone for menopause diagnosis. Am J Obstet Gynecol. 2004;190(5):1272–1277.
   PubMed Web of Science ®Google Scholar